Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II (NCT06615102) | Clinical Trial Compass
RecruitingPhase 3
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
Germany1,022 participantsStarted 2025-03-31
Plain-language summary
The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Cardiac surgery using cardiopulmonary bypass including coronary artery bypass grafting (CABG) surgery, valve surgery, or combined CABG/valve surgery
✓. Elevated risk of AKI as predicted by a score ≥ 1.5 on the following scale:
✓. hemoglobin \< 130g/l = 2
✓. creatinine \> 1.1 mg/dl = 2
✓. age \> 70 years =1.5
✓. New York Heart Association Classification (NYHA) 4 =1.5
✓. Body Mass Index (BMI) \> 30 =1.5
✓. Adult ≥ 18 years
Exclusion criteria
✕. Major aortic surgery (aortic arch replacement), transplant surgery, pulmonary thrombendarterectomy, ventricular assist device placement
✕. Already receiving inotropic/vasopressor support before surgery
What they're measuring
1
Rate of AKI KDIGO stage 2 or 3 or death within 72 hours after end of cardiac surgery.